IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+1.51%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$268M
AUM Growth
+$268M
(+146%)
Cap. Flow
+$165M
Cap. Flow
% of AUM
61.61%
Top 10 Holdings %
Top 10 Hldgs %
45.87%
Holding
138
New
35
Increased
22
Reduced
7
Closed
15
Top Buys
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$21.5M |
| 2 |
Verastem
VSTM
|
$13.9M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$13.6M |
| 4 |
BioXcel Therapeutics
BTAI
|
$12M |
| 5 |
argenx
ARGX
|
$8.68M |
Top Sells
| 1 |
APTO
Aptose Biosciences, Inc.
APTO
|
$5.73M |
| 2 |
KALA BIO
KALA
|
$4.65M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
$3.81M |
| 4 |
TG Therapeutics
TGTX
|
$3.51M |
| 5 |
ARQL
Arqule Inc
ARQL
|
$2.97M |
Sector Composition
| 1 | Healthcare | 98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
1
DELISTED
Acceleron Pharma Inc.
XLRN
| $21.5M | 1.62% | +239,249 | New | +$21.5M |
|
|
2
BioXcel Therapeutics
BTAI
$59M
| $15.5M | 1.17% | 693,716 +535,343 | +338% | +$12M |
|
|
3
Verastem
VSTM
$569M
| $13.9M | 1.04% | +5,252,427 | New | +$13.9M |
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $13.6M | 1.02% | +549,459 | New | +$13.6M |
|
5
Immunovant
IMVT
$2.56B
| $13.1M | 0.99% | 842,463 +338,346 | +67% | +$5.27M |
|
6
Protara Therapeutics
TARA
$120M
| $10.4M | 0.78% | 450,772 +114,399 | +34% | +$2.63M |
|
|
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $9.97M | 0.75% | 3,638,000 +1,799,472 | +98% | +$4.93M |
|
|
8
argenx
ARGX
$43.6B
| $8.68M | 0.65% | +65,856 | New | +$8.68M |
|
9
Ardelyx
ARDX
$1.53B
| $8.31M | 0.63% | 1,462,234 +816,798 | +127% | +$4.64M |
|
10
scPharmaceuticals
SCPH
$295M
| $7.95M | 0.6% | +1,073,647 | New | +$7.95M |
|
11
Ocular Therapeutix
OCUL
$2.12B
| $7.72M | 0.58% | 1,558,936 +1,001,277 | +180% | +$4.96M |
|
|
CHMA
12
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $7.58M | 0.57% | 2,075,492 +972,195 | +88% | +$3.55M |
|
13
Kura Oncology
KURA
$686M
| $7.56M | 0.57% | +759,803 | New | +$7.56M |
|
|
TVRD
14
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $7.29M | 0.55% | +552,163 | New | +$7.29M |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $7.24M | 0.54% | 946,605 +734,185 | +346% | +$5.62M |
|
|
SBBP
16
DELISTED
Strongbridge Biopharma plc.
SBBP
| $6.41M | 0.48% | +3,392,787 | New | +$6.41M |
|
17
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $5.56M | 0.42% | +358,924 | New | +$5.56M |
|
|
KDMN
18
DELISTED
Kadmon Holdings, Inc.
KDMN
| $5.52M | 0.42% | +1,316,846 | New | +$5.52M |
|
|
SAGE
19
DELISTED
Sage Therapeutics
SAGE
| $5.26M | 0.4% | 183,051 +50,051 | +38% | +$1.44M |
|
20
Xenon Pharmaceuticals
XENE
$2.98B
| $5.03M | 0.38% | 443,582 +200,112 | +82% | +$2.27M |
|
|
21
KALA BIO
KALA
$78.8M
| $4.34M | 0.33% | 493,952 -529,479 | -52% | -$4.65M |
|
|
TCDA
22
DELISTED
Tricida, Inc. Common Stock
TCDA
| $3.96M | 0.3% | +179,800 | New | +$3.96M |
|
|
ITCI
23
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.83M | 0.29% | +249,002 | New | +$3.83M |
|
|
BMY.RT
24
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $3.61M | 0.27% | +950,000 | New | +$3.61M |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $3.5M | 0.26% | +2,366,850 | New | +$3.5M |
|